Vasodilator Drugs: Chronic Vasodilator Therapy - Other Vasodilators
General (including evidence of efficacy)
Other orally administered vasodilators
Calcium channel blockers
Available studies including several multicenter controlled trials have not determined a role for their application in dilated cardiomyopathy (ischemic and nonischemic) and heart failure. The results either show no net effect or a detrimental effect on the clinical course. This applies to the dihydropyridines (e.g., nifedipine, amlodipine) and diltiazem. Although studies in diastolic heart failure are limited at the present time, there is little to suggest a role for calcium channel blockers for this patient group.
Large multicenter controlled trials are not available for sildenafil and thus this drug is not approved for use in heart failure. Initial small reports indicate that this agent may have a role in heart failure with or without concomitant pulmonary hypertension. In these early preliminary studies in heart failure, sildenafil improves exercise capacity, quality of life, and perhaps diastolic performance.
Pentoxifylline, perhexiline, and trimetazidine are awaiting large multicenter trials to establish effectiveness and potentially a role in the management of heart failure.
What's the Evidence?
Cohn, JN, Ziesche, S, Smith, R. " Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patient with chronic heart failure treated with enalapril: V-HeFT III". Circulation. vol. 96. 1997. pp. 856-863.(This is just one of many large controlled trials showing that calcium-channel blocking agents are of limited value in the management of chronic systolic heart failure.)
Lewis, GD, Shah, R, Shahzad, K. " Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension". Circulation. vol. 116. 2007. pp. 1555-1562.(A preliminary placebo-controlled study showing that another vasodilator with some promise, sildenafil, may have a beneficial effect on symptoms and exercise performance.)
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|